Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Oncopeptides AB ( (SE:ONCO) ).
Oncopeptides has announced new research demonstrating that its multiple myeloma drug Pepaxti (melflufen) maintains strong anti-myeloma activity in patients with high-risk genetic abnormalities such as del(17p) and TP53 mutations, which are typically associated with more aggressive, treatment-resistant disease. The collaborative study from Finland, Germany and Sweden showed consistent in vitro activity across genetic subgroups, a mechanism of action that does not depend on functional TP53, and post-hoc clinical data from the phase 3 OCEAN trial indicating longer progression‑free survival versus pomalidomide-based therapy in del(17p) patients, bolstering the differentiation of Pepaxti and Oncopeptides’ PDC platform versus conventional alkylators and reinforcing the drug’s role in treating some of the most challenging myeloma cases, with potential to strengthen the company’s positioning among haematology specialists and investors.
The most recent analyst rating on (SE:ONCO) stock is a Hold with a SEK5.50 price target. To see the full list of analyst forecasts on Oncopeptides AB stock, see the SE:ONCO Stock Forecast page.
More about Oncopeptides AB
Oncopeptides AB is a Swedish biotech company specializing in targeted therapies for difficult-to-treat cancers, leveraging its proprietary Peptide Drug Conjugate (PDC) and SPiKE platforms to deliver cytotoxic agents selectively into cancer cells. Its flagship drug Pepaxti (melflufen) is approved in the EU, EEA and UK for heavily pre-treated multiple myeloma patients and is being commercialized in Europe with partnership agreements in South Korea, the Middle East, Africa and other regions, supported by a workforce of about 80 employees across Sweden, Germany, Austria, Spain and Italy and a listing on Nasdaq Stockholm under the ticker ONCO.
Average Trading Volume: 2,392,165
Technical Sentiment Signal: Hold
Current Market Cap: SEK1.18B
See more insights into ONCO stock on TipRanks’ Stock Analysis page.